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Pharmacokinetics of amikacin in children with normal and impaired
renal function. The pharmacokinetics of the antibiotic amikacin sulfate
were studied in eight children with normal renal function and in ten
children with varying degrees of renal impairment. All patients received
a single i.v. dose of 7.5 mg/kg of the antibiotic. Amikacin follows a two-
compartment open-kinetic model, The serum half-life, which in children
with normal renal function has an average value of 1 hour, reached
values of 14 hours in children with severe renal impairment. A lineal
relationship is established between the 13 constant and the creatinine
clearance (Clcr) according to the equation 3 = 0.001 + 0.005 Clcr, with
r = 0,818. From this equation, the dosage interval is modified to
maintain the serum concentrations of the antibiotic within the therapeu-
tic interval.
Pharmacocinetique de l'amikacine chez les enfants indemnes ou non
d'insuffisance rénale. La pharmacocinétique de l'amikacine a été étu-
diée chez huit enfants ayant une fonction rénale normale et dix enfants
atteints d'insuffisance rénale a degrés divers. Tous onE recu une dose
unique, par voie i.v. de 7,5 mg/kg. L'amikacine obéit a un modèle de
deux compartiments ouverts. La demi vie sérique qui chez l'enfant dont
La fonction rénale est normale a une valeur de I heure atteint des valuers
de 14 heures chez les enfants atteints d'insuffisance rénale sévère. Une
relation linéaire est établie entre la constante 3 et Ia clearance de la
créatinine (Cler) selon l'équation $3 = 0,001 + 0,005 Cl,r, avec r =
0,818. A partir de cette equation Ia frequence d'administration est
modifiée afin de maintenir les concentrations seriques de l'antibiotique
dans l'intervalle thCrapeutique.
The proliferation of infectious processes caused by Gram-
positive and Gram-negative germs resistant to gentamicin has
led to an increase in the use of semisynthetic aminoglycosides,
which, like amikacin, are stable against many enzymes that
inactivate this group of antibiotics [1, 2]. Various clinical
studies have shown favorable results in the treatment of infec-
tious processes caused by Gram-negative bacteria in the new
born, infants, and children [3—5]. The pharmacokinetics of
amikacin in adults are known, although in most of the studies
that have been carried out the form of administration has been
i.v. perfusion or intramuscular [6, 7].
Amikacin, like the other aminoglycosides, is principally
eliminated by glomerular filtration, and very high urine concen-
trations are reached [8]. In states of renal impairment, impor-
tant modifications are caused in the pharmacokinetics of the
antibiotic, as has been shown in various studies carried out on
adult patients [9, 10]. These modifications in the pharmacoki-
netics mainly affect the elimination rate and impose the need to
correct the dosage regimen to avoid an accumulation of the
antibiotic within the organism.
Studies on the pharmacokinetics of aminoglycosides in chil-
dren with renal impairment are rare [11], though interest in
them is highly justifiable due to the reduced safety margin and
to the massive renal excretion that takes place in this group of
antibiotics.
Methods
Patients. The study included 18 hospitalized patients of
which 8 had normal renal function (creatinine clearance, 136 to
70 mllmini73 m2), and the remaining 10 showed varying
degrees of renal impairment. Tables I and 2 show some of the
clinical characteristics of the patients, including the serum urea
and creatinine concentrations together with creatinine clear-
ance, used as an index of renal function. Informed consent to
participate in the study was obtained from the parents.
Administration of the antibiotic and collection of the sam-
ples. All patients received a single-bolus-type i.v. injection of
7.5 mg/kg of amikacin sulfate. Blood samples were withdrawn
at the following times. In patients with normal renal function,
they were obtained at 0 (immediately before administration of
the antibiotic), 0.25, 0.5, 0.75, 2.0, 4.0, and 6.0 hours. In
patients with renal impairment, they were obtained at 0, 0.5,
2.0, 4.0, 8.0, 12.0, and 16.0 hours. All samples were centrifuged
to separate the serum and stored at —20° C until their later
determination. None of the patients had received any treatment
with antibiotics during the 72 hours prior to beginning the study.
Analytic technique. The determination of the antibiotic in
serum was carried out by a microbiologic plate-diffusion meth-
od using Bacillus subtilis (ATCC no. 6633) as the test organism.
Standard curves of amikacin in pooled human serum were
prepared with concentrations of the antibiotic between 50 and
0.'S p.g/ml. The variation coefficient of the technique was less
than 5%, and the lower sensitivity limit was 0.3 g/mL. All
determinations were carried out four times, using a total of 80 pA
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Table 1. Clinical parameters of the eight pediatric patients with normal renal function
Patient no.
Age
yr
Serum Creatinine
Serum urea creatinine clearance Total
Wt (Ce) (Ccr) (Clcr) protein
Sex kg gid! mg/dl mi/mm 1.73 m2 g/dl
Dosage
mg
Surface
area
m2
1
2
3
4
5
6
7
8
5
4
5
11
7
4
3
8
M 16 0.32 0.42 91 6.68
F 17 0.31 0.48 103 7.31
M 15 0.27 0.53 86 6.73
M 26 0.43 0.64 136 7.00
F 23 0.18 0.59 64 7.10
F 18 0.16 — — 6.80
M 15 0.21 0.52 128 6.70
F 22 0.53 0.54 90 7.21
120
131
111
198
170
134
116
162
0.70
0.67
0.60
1.02
0.86
0.71
0.64
0.87
Table 2. Clinical parameters of the ten pediatric patients with renal insufficiency
Patient no.
Age
yr
Serum Serum Creatinine
urea creatinine clearance Total
Wt (Ce) (Ccr) (Cler) protein
Sex kg gidi mg/dl mi/mm . 1.73 m2 gIdi
Dose
mg
Surface
area
m2
1
2
3
4
5
6
7
8
9
10
11
11
1.5
3
1.10
10
7
10
4
7
M 18 2.18 7.15 5 8.60
M 35 0.64 1.27 46 8.00
M Il 0.98 1.37 16 7.15
M 10 0.25 0.27 64 6.73
M 9 0.64 1.09 34 6.95
M 33 0.33 0.88 79 7.73
M 21 0.55 1.20 51 6.50
F 28 0.45 0.96 40 7.73
M 17 0.42 0.46 63 7.78
F 31 0.21 0.60 60 6.90
135.0
265.0
82.5
75.0
69.5
248.0
160.0
210.0
129.0
232.0
0.74
1.13
0.49
0.47
0.43
1.12
0.80
1.00
0.70
0.98
of serum. No variations were observed in the diffusion in agar
of the antibiotic incorporated into uremic serum in comparison
with normal serum.
Pharmacokinetic analysis. Administered intravenously, ami-
kacin follows a two-compartment open-kinetic model. The
pharmacokinetic parameters were established from the experi-
mental values of the serum concentrations using a Hewlett-
Packard 67 programmable calculator. The equations used to
establish the different pharmacokinetic parameters correspond-
ing to this model are shown in the Appendix to this article.
The serum concentration of amikacin at steady state (C)
during a multiple dosage regimen was calculated from the
following expression:
D
css = Cl .
where D represents the maintenance dose administered, Cl is
the serum clearance of the antibiotic, and r the dosage interval.
The dosage interval in patients with renal impairment (Tr)was
established by the method of Dettli [12] and may be obtained
from the following expression:
r = 1
where T corresponds to the dosage interval used in patients with
normal renal function and and 1' are the values of 3 constant
in patients with normal renal function and renal impairment,
respectively. The statistical significance, (statistical compari-
son) between the values of the serum concentration and the
varying pharmacokinetic parameters was obtained by Student's
test. The P value was used to establish the level of signifi-
cance.
Results
Figure 1 shows the mean serum concentration curve of
amikacin in children with normal renal function (N 8)
receiving a single dose of 7.5 mg/kg of the antibiotic. The serum
concentrations fall from 75.94 (a concentration value of zero
[C0] obtained by extrapolation) to 14.54 .g/ml, 0.91 hours after
administration, coinciding with the distribution equilibrium.
Six hours after administration, the serum concentrations
have an average value of 0.62 p.g/ml, whereas at 8 hours they
are undetectable according to the analytic technique used. The
average pharmacokinetic parameters in this group of patients
are shown in Table 3.
Table 4 shows the serum concentrations of Amikacin ob-
tained in 10 children with varying degrees of renal impairment
determined in the 16 h following administration of the antibiot-
ic. The pharmacokinetic parameters established in this group of
patients are shown in Table 5.
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Discussion
The average serum concentration curve of amikacin obtained
from the patients with normal renal function has a biexponential
plot, similar to that observed in adults [131. This shows that
there is a certain affinity towards the peripheral tissues. The
serum concentrations of amikacin obtained 6 hours after admin-
istration are lower than those established by Kafetzis et al [14],
which have an average value of 2.0 0.3 p.g/ml. This value,
however, was obtained in three children with an average age of
3.1 years, and it is an established fact that the elimination rate of
drugs increases progressively from birth until 12 to 16 years,
when drug clearance is even greater than that of adults with
normal renal function [13].
The serum concentrations of amikacin in children with nor-
mal renal function, during the period of time studied, are
maintained at values significantly lower (P = 0.05) than those
obtained in adults receiving the same dose. These differences
may be seen in the pharmacokinetic parameters of the antibiot-
ic, in particular those that define the elimination process. The
serum t'/2 of the slow disposition phase has an average value of
1.19 0.19 hours, significantly lower (P = 0.01) than that
established in this laboratory in a similar study carried out on
adults with normal renal function, and which was 2.30 hours
[13]. Values reported by other authors oscillate between 2 and 3
hours, according to the methods used [141. The value of t1/2 for
13 obtained by us coincides with that previously established by
Kramer et aT [15], which was 1.2 hours, though less than that
reported by Volgestein, Kowarski, and Lietman [16], which
was 1.6 hours, and Kafetzis et al [141, which was 2.04 hours.
The variations in the half-life values of amikacin iii children are
doubtless due to methodologic differences, such as the adminis-
tration route, age, the kinetic model used, the analytical
technique, and so on; these have already been commented on
by Kramer.
a Values are the means Symbols are defined in the Appendix.
The increase in the elimination constant in children as
compared with adults has also been observed in kanamycin [171
and gentamicin [18]. This increase in the elimination rate is
considered as being "apparent" by some authors who believe
that the true distribution equilibrium is not reached until more
than 10 hours after administration. Evans et al [19], in a recent
study on the pharmacokinetics of gentamicin in children under-
going prolonged treatment, demonstrated that the distribution
equilibrium is not reached until 4 days after the last injection.
This equilibrium is produced at low serum concentrations, less
than 0.1 g/m1, and is established between the antibiotic in
serum and that accumulated in deep tissue, especially in the
renal cortex and medulla. The terminal half-life of gentamicin in
the same study did not differ from that established in adults by
other authors. The apparent half-life, however, which corre-
sponds to that observed in the dosage interval, decreases in
adults. This is similar to the situation in our study.
From the pharmacokinetic parameters of amikacin for a dose
of 7.5 mg/kg administered at intervals of 12 hours, a regimen
that is most consistently used for this antibiotic, the predictable
steady-state concentration of the antibiotic (C5) should be 3.71
xgIml, significantly different (P = 0.05) from that established in
adults (8.82 g/ml). Bearing in mind this decrease in the
equilibrium concentration that takes place in a multiple-dosage
regimen, the possibility exists of increasing the dosage of the
antibiotic for this kind of patient. In a study carried out on eight
pediatric oncology patients, Kramer et al [15] used a dosage of
20 mg/kg/day due to the decrease observed in the half-life
values and to the slight increase in the apparent distribution
volume of the antibiotic. No signs of a possible accumulation
were observed. Due to the scarcity of work, including pharma-
cokinetic, clinical, and toxicological data of the antibiotic at a
dosage of 20 mg/kg/day in this kind of patient, the increase in
dosage should be effected with great care, monitoring the
patient's serum concentrations of the antibiotic, urea, and
creatinine. The total dose may be divided in two to four daily
administrations.
The apparent distribution volume in children with normal
renal function has an average value of 0.19 1/kg, slightly larger
than that established in adults with a normal renal function of
0.18 liters/kg [131. But, in spite of the analogy between the
values of the apparent distribution volume, the relationship
between the microconstants K12/K21 is significantly modified,
falling from 2.58 in adults to 0.81 in children, indicating that
contrary to what happens in adults, the distribution volume of
the central compartment in children is greater than that of the
peripheral compartment. This is attributable to the relative
increase in the extracellular fluid shown by children as com-
pared with adults.
20
Table 3. Average pharmacokinetic parameters of amikacin in children
with normal renal functiona
4
I
tV2 a, hr
t'/2 3, hr
K12, hr'
K21, hr'
K13, hr'
C1, mi/mm kg
0.251 0.117
1.193 0.194
1.034 0.615
1.217 0.301
1.631 0.673
3.008 1.247
V liters
VP liters
, liters/kg
2.272 1.389
1.767 1.909
0.198 0.107
0.4
1 2 3 4 5
Time, hours
Fig. 1. Average serum concentration curve (±sD) of amikacin in
children with normal renal function (N = 8).
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Table 4. Serum concentrations of amikacin in ten children with renal impairment
Serum concentration of amikacin, pg/ml
Time
hr
Patient
1
Patient Patient Patient Patient Patient Patient Patient Patient
2 3 4 5 6 7 8 9
Patient
10
0.50
2.00
4.00
8.00
12.00
16.00
63.75
24.30
19.47
14.47
9.99
9.01
40.86 24.28 9.39 23.17 38.24 33.41 29.98 20.41
24.32 15.10 2.96 13.00 15.10 9.41 14.67 8.02
14.47 5.46 0.82 7.09 10.62 6.31 8.95 2.98
6.00 3.17 0.10 3.16 2.11 3.24 3.71 0.35
4.76 2.11 0.07 2.25 0.82 2.03 2.03 0.20
3.05 0.94 0.06 1.31 0.45 0.75 0.71 0.12
35.36
9.47
7.18
0.94
0.37
0.21
Table 5. Pharmacokinetic parameters of amikacin established in ten children with renal impairmenta
Patient
no.
t'/2a
hr
t'/2 K12 K21 K13 V V, C
hr hr' hr' hr1 liters liters mi/mm/kg liters/kg
1
2
3
4
5
6
7
8
9
10
0.81
1.50
0.61
0.95
1.18
1.62
1.40
0.41
1.19
1.41
11.74 0.44 0.32 0.16 1.98 2.72 0.29
8.25 0.15 0.18 0.22 5.42 4.54 0.56
4.93 0.47 0.37 0,42 1.96 2.48 1.25
13.59 0.36 0.29 0.13 3.79 4.79 0.81
6.24 0.18 0.24 0.27 2.40 1.86 1.18
3.59 0.04 0.25 0.33 6.33 1.01 1.06
4.03 0.80 0.49 0.60 2.51 4.09 1.17
3.27 0.57 0.95 0.38 4.95 2.98 1.10
4.91 0.05 0.16 0.51 4.99 1.53 2.48
3.73 0.04 0.22 0.41 6.79 1.29 1.51
0.26
0.28
0.40
0.86
0.46
0.22
0.30
0.28
0.38
0.26
a Symbols are defined in appendix.
Figure 2 shows the serum concentration curve of amikacin in
three children with varying degrees of renal function (creatinine
clearances of 120, 50, and 5 mi/mm 1.73 m2). Parallel to the
deterioration in renal function, at first, a progressive decrease
in the elimination rate of the antibiotic is produced. As a
consequence, on initiating a multiple dosage regimen, the usual
form of antiinfectious therapy, an accumulation of the antibiotic
will take place if the dosage intervals are not modified adequate-
ly. Renal impairment induces several modifications in the
pharmacokinetics of amikacin, similar to those already estab-
lished in adult patients [131. Thus, it has been established that in
these patients, the values of a, 13, K12, K21, K13, and Cl5
decrease, whereas the (AUC)°, and Vd55 increase in comparison
with those determined in children with normal renal function.
The changes that these pharmacokinetic parameters undergo is
conditioned by the degree of deterioration in renal function and
becomes manifest when the creatinine clearance is less 30 ml!
min 1.73 m2.
Figures 3 and 4 show the linear relationships established
between the rapid and slow disposition rate constants with the
corresponding creatinine clearances, which are defined by the
following equations:
a (hr') = 0.219 + 0.030 Clcr (mi/mm 1.73 m2)
with r = 0.709 (N = 17).
13 (hr') 0.001 + 0.005 Clcr (mi/mm 1.73 m2)
with r = 0.818 (N = 16).
The variation of the constant a with creatinine clearance
indicated a delay in the distribution of the antibiotic in the case
of renal impairment. The variation observed in these pharmaco-
kinetic parameters is greater than that described in adults, there
being an increase in the slopes of the above equations of 30 and
150%, respectively.
The relationship between the constant Cl, and the creatinine
clearance is exponential and may be defined by the following
equation:
Cl5 (mi/mm kg) = 0.478 e°'°'8 (mi/mm 1.73 m2
with r = 0.736 (N = 16). This equation may be used to calculate
the value of the Cl5 constant in the varying degrees of renal
impairment.
The most significant modification produced in the pharmaco-
kinetics of amikacin in children with renal impairment is the
decrease in the elimination rate of the antibiotic, inducing
important increases in the serum half-life. On occasion, for the
same degree of renal impairment, the serum half-life of the
antibiotic is less than that established in adults, similar to what
has been observed in children with normal renal function.
Figure 5 shows the values of the 13 half-life calculated in
children and adults for three different degrees of renal impair-
ment.
Figure 6 shows the relationship established between the
distribution coefficient of amikacin and the creatinine clearance
defined by the following equation:
A (liters/kg) = 0.404 — 0.002 Cler (mi/mm 1.73 m2)
with r = 0.729 (N = 14)
Similar to the situation in adult patients, the distribution
volume of amikacin is increased in renal impairment [13]. But,
analogous to what happens with other pharmacokinetic parame-
ters, the variation is more significant in children than in adults,
10I
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20
4
.
.
0.4
0
.
.
S
5
4
C
C
0
40 80 120 160
Creatinine clearance, mI/rn in/i. 73 m2
Fig. 3. Linear relationships established between the a constant and the
creatinine clearance.
C
0
. .
4 8 12 16 20
Time, hours
Fig. 2. Serum concentration of amikacin in three children with varying
degrees of renal function with creatinine clearance of 120 (s), 50 (0),
and 5 (') mI/mm 1.73 m2.
Adults
.
40
I
Children
20
0.3
0.1
10
125 20 5 125 20
Creatinine clearance, mI/mm 1.73 m2
Fig. 5. Serum half-life (t'/213) of amikacin calculated from the pharma-
cokinetic parameters in children and adults with varying degrees of
renal function.
40 80 120
Creatinine clearance, mI/mm 1.73 m2
Fig. 4.Linear relationships established between the 13 constant and the
creatinine clearance (two points statistically excluded).
as may be seen from the increase in the slope of the previous
equation, representing 67%.
As a consequence of the accumulation of the antibiotic in the
systemic circulation in renal impairment, modifications are
caused in the access to and presence within peripheral tissues.
Figure 7 shows the amounts of amikacin in the peripheral
compartment calculated from pharmacokinetic parameters ob-
tained in children with normal renal function and in one child
with severe renal impairment. This fact has been confirmed in
our laboratory in studies carried out on animals with experi-
mentally induced renal impairment [20].
Because of the possible accumulation in children with renal
impairment and the toxicologic effects of aminoglycoside drugs,
a correction in the dosage regimen becomes necessary. The
20 40 60 80 100 120 140
Creatinine clearance, mI/mm 1.73 m2
method used is based on holding the maintenance dosage
constant and progressively increasing the dosage interval ac-
cording to the deterioration in renal function. As in pediatric
patients with normal renal function, the maintenance dosage
may be established at 7.5 or 10.0 mg/kg, depending on the
severity of the infectious process and the criteria of the physi-
cian.
Table 6 shows the dosage intervals calculated as a function of
the creatinine clearance in this kind of patients. In some cases,
the application of the proposed intervals may originate concen-
trations below MIC, especially in patients with advanced de-
grees of renal impairment. As a consequence, a systematic
monitoring of the serum concentrations of the antibiotic, urea,
and creatinine becomes necessary in the patients. The omission
in Table 6 of the intervals applicable to patients with terminal
renal impairment is due to the necessity of modifying the dosage
regimen according to the dialysis sessions.
In this type of patient, the maintenance dose may also be
corrected, keeping the dosage interval the same, according to
the following expression:
D C15rDr - ____
C's
Administered iv,, amikacin follows a two-compartment open-kinetic
model. The serum concentration curve of the antibiotic is defined by the
following equation: C = Ao.e_t + B0et
A0 and B0 are the serum concentrations at time (t) = 0of the rapid and
slow disposition phases whose constants are a and 13. The constants A0,
B0, a and 13, were determined by a programmable Hewlett-Packard-67
computer. The serum concentration at t = 0 (C0), the half-life of the
rapid and slow disposition phases (tY2a, t'/213), the distribution con-
stants K12 and K21, the overall elimination rate constant (K13), the
Time, hours
Fig. 7. Amounts of amikacin in the peripheral compartment calculated
from pharmacokinetic parameters in children with normal renal func-
tion (—) and in one child with severe renal impairment (--).
Creatinine clearance
(Clcr)
ml/min 1.73 m2
A
hr
B
hr
120 8to12 4to6
100 lOtol4 5to7
80 l2tol8 6to9
60 l6to24 8to12
40 24to36 12to18
20 48to72 24to36
central (Vs), peripheral (V0) and the steady-state (Vd55) apparent
distribution volumes, the distribution coefficient (s), and the serum
clearance (Cl5) are calculated from the following expressions [21, 22].
0.693 0.693
C0 = A0 + B0; t'/2a = ; tt/213 =a 13
Ao.Bo(a—13)2 D
K12 =
C0 (A0 13 + B0 a)' V = K13
K12 K12 + K21
VP = V;Vd5, = V
K21 K21
Vd5,Cl, = K13 'Va; =
weight
where D = dose.
The amounts of antibiotic in the peripheral compartment (A0) were
calculated from the following expression.
D K12
A0 =
a — 13
(e_IOt — e1)
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